CTCs
Biocept Licenses CNSide Liquid Biopsy Assay to Plus Therapeutics
Under the agreement, Plus is using the cerebrospinal fluid cell-based assay in its ongoing clinical trial of the radiotherapeutic rhenium 186 obisbemeda.
Angle, BioView Partner to Develop Quantitative HER2 Assay Using Circulating Tumor Cells
The companies said recent developments in HER2-targeted therapies have created new commercial opportunities for a blood-based test.
The company's LungLB blood-based circulating tumor cell assay performed well in evaluating indeterminate lung nodules found in CT scans in a pilot study.
The firm believes its Orion system's combination of multiplexing, data quality, and throughput will help it carve out a space in an increasingly crowded market.
The firm cited new study results confirming that an assay analyzing circulating tumor cells isolated by its Parsortix platform can discriminate malignant pelvic masses.